Premium
In vitro drug‐induced cytotoxicity predicts clinical response to fludarabine in B‐cell chronic lymphocytic leukaemia
Author(s) -
Morabito Fortunato,
Stelitano Caterina,
Callea Ida,
Dattola Antonella,
Console Giuseppe,
Pucci Giulia,
Iacopino Pasquale,
Callea Vincenzo,
DI Raimondo Francesco,
Brugiatelli Maura
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00813.x
Subject(s) - fludarabine , cytotoxicity , chronic lymphocytic leukemia , in vitro , in vivo , chemistry , medicine , immunology , chemotherapy , leukemia , biology , biochemistry , cyclophosphamide , microbiology and biotechnology
We investigated the possible value of an in vitro drug‐induced cytotoxicity assay in predicting clinical response to fludarabine (FAMP) in chronic lymphocytic leukaemia (CLL). The median FAMP‐LD 50 values for cases designated as complete response (CR), partial response (PR), no response (NR) and progressive disease (PD) were 1.43, 2.05, 24.8 and 77.9 μg/ml, respectively ( P =0.013). A significant lower mean FAMP‐LD 50 value was observed in the in vivo responding cases as compared to non‐responding ones (3.0 ± 0.82 SEM v 42.3 ± 12.6 SEM, P =0.001). Only FAMP‐LD50 2.5 μg/ml and more than four FAMP courses significantly influenced the response rate in univariate and multivariate analyses. The MTT assay may be of value in predicting clinical response to FAMP in CLL patients.